Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: Lessons from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists Academic Article Article uri icon

Overview

MeSH Major

  • Angioplasty, Balloon, Coronary
  • Coronary Artery Disease
  • Drug-Eluting Stents
  • Heart Transplantation

abstract

  • Glycoprotein IIb-IIIa antagonism with abciximab is equally effective in prevention of a composite of ischemic events in patients with and without high-risk features after stent placement. However, patients in whom high-risk features are present after stent placement are at increased risk of ischemic cardiac events even with abciximab treatment.

publication date

  • May 9, 2002

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1067/mhj.2002.121519

PubMed ID

  • 11923795

Additional Document Info

start page

  • 594

end page

  • 601

volume

  • 143

number

  • 4